Assessment Of Safety Of UK-390,957

Back to Search
Print
Bookmark Trial

NCT00219609

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Tucson, Arizona, , United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ejaculation
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- No drug related serious adverse events

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

EjaculationAssessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
NCT00219583
  1. Bondi Junction, New South Wales
  2. St Leonards, New South Wales
  3. Spring Hill, Queensland
  4. Adelaide, South Australia
  5. Malvern, Victoria
  6. Nedlands, Western Australia
  7. Mistelbach,
  8. Salzburg,
  9. Edmonton, Alberta
  10. Victoria, British Columbia
  11. London, Ontario
  12. Oakville, Ontario
  13. Toronto, Ontario
  14. Montreal, Quebec
  15. Montréal, Quebec
  16. Brno,
  17. Hradec Kralove,
  18. Prague 5,
  19. Praha 2,
  20. Le Kremlin Bicetre,
  21. Lyon Cedex 03,
  22. Muenchen, Bavaria
  23. Hamburg,
  24. Hannover,
  25. Muenchen,
  26. Beer Sheba,
  27. Haifa,
  28. Jerusalem,
  29. Tel Hashomer,
  30. Tel- Aviv,
  31. Milan,
  32. Roma,
  33. Den Haag,
  34. Nijmegen,
  35. Bodø,
  36. Moelv,
  37. Oslo,
  38. Bialystok,
  39. Kielce,
  40. Myslowice,
  41. Warszawa,
  42. Sabadell, Barcelona
  43. Barcelona,
  44. Madrid,
  45. Malaga,
  46. Skovde,
  47. Stockholm,
  48. Balcali, Adana
  49. Samanpazari, Ankara
  50. Balcova, Izmir
Male
18 Years+
years
MULTIPLE SITES
EjaculationAssessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT00143117
  1. Tucson, Arizona
  2. Anaheim, California
  3. Atherton, California
  4. Beverly Hills, California
  5. Laguna Woods, California
  6. Newport Beach, California
  7. Redwood City, California
  8. San Diego, California
  9. Tarzana, California
  10. Walnut Creek, California
  11. Aurora, Colorado
  12. Waterbury, Connecticut
  13. Aventura, Florida
  14. New Port Richey, Florida
  15. Pembroke Pines, Florida
  16. Evansville, Indiana
  17. Fort Wayne, Indiana
  18. Indianapolis, Indiana
  19. Michigan City, Indiana
  20. Lexington, Kentucky
  21. Madisonville, Kentucky
  22. Metairie, Louisiana
  23. Milford, Massachusetts
  24. St. Clair Shores, Michigan
  25. Minneapolis, Minnesota
  26. Southhaven, Mississippi
  27. Kansas City, Missouri
  28. Reno, Nevada
  29. Edison, New Jersey
  30. New Brunswick, New Jersey
  31. Voorhees, New Jersey
  32. Albany, New York
  33. Endwell, New York
  34. New York, New York
  35. West Seneca, New York
  36. Williamsville, New York
  37. Charlotte, North Carolina
  38. Durham, North Carolina
  39. Beachwood, Ohio
  40. Tulsa, Oklahoma
  41. Germantown, Tennessee
  42. Knoxville, Tennessee
  43. Memphis, Tennessee
  44. Milan, Tennessee
  45. Dallas, Texas
  46. Fort Worth, Texas
  47. Houston, Texas
  48. Plano, Texas
  49. San Antonio, Texas
  50. Tacoma, Washington
  51. Milwaukee, Wisconsin
Male
18 Years+
years
MULTIPLE SITES
EjaculationAssessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
NCT00219635
  1. Birmingham, Alabama
  2. San Bernardino, California
  3. Metairie, Louisiana
  4. Watertown, Massachusetts
  5. Kansas City, Missouri
  6. Washington, Missouri
  7. New York, New York
  8. Williamsville, New York
  9. Beachwood, Ohio
  10. Portland, Oregon
  11. Knoxville, Tennessee
  12. Dallas, Texas
  13. Houston, Texas
  14. Milwaukee, Wisconsin
  15. St Leonards, New South Wales
  16. Malvern, Victoria
  17. Victoria, British Columbia
  18. Barrie, Ontario
  19. London, Ontario
  20. Toronto, Ontario
  21. Nr Lichfield, Staffordshire
  22. Devon,
Male
18 Years+
years
MULTIPLE SITES
EjaculationAssessment Of Safety Of UK-390,957
NCT00219609
  1. Tucson, Arizona
  2. Anaheim, California
  3. Atherton, California
  4. Beverly Hills, California
  5. Laguna Woods, California
  6. Newport Beach, California
  7. Redwood City, California
  8. San Diego, California
  9. Tarzana, California
  10. Walnut Creek, California
  11. Aurora, Colorado
  12. Waterbury, Connecticut
  13. Aventura, Florida
  14. New Port Richey, Florida
  15. Evansville, Indiana
  16. Fort Wayne, Indiana
  17. Indianapolis, Indiana
  18. Lexington, Kentucky
  19. Madisonville, Kentucky
  20. Metairie, Louisiana
  21. Watertown, Massachusetts
  22. Saint Clair Shores, Michigan
  23. Minneapolis, Minnesota
  24. Southhaven, Mississippi
  25. Kansas City, Missouri
  26. Edison, New Jersey
  27. New Brunswick, New Jersey
  28. Vorhees, New Jersey
  29. Albany, New York
  30. Endwell, New York
  31. New York, New York
  32. West Seneca, New York
  33. Williamsville, New York
  34. Charlotte, North Carolina
  35. Durham, North Carolina
  36. Beachwood, Ohio
  37. Portland, Oregon
  38. Germantown, Tennessee
  39. Knoxville, Tennessee
  40. Memphis, Tennessee
  41. Milan, Tennessee
  42. Dallas, Texas
  43. Houston, Texas
  44. San Antonio, Texas
  45. Milwaukee, Wisconsin
  46. Milwuakee, Wisconsin
  47. St Leonards, New South Wales
  48. Spring Hill, Queensland
  49. Adelaide, South Australia
  50. Malvern, Victoria
  51. Nedlands, Western Australia
  52. Mistelbach,
  53. Salzburg,
  54. Barrie, Ontario
  55. London, Ontario
  56. Oakville, Ontario
  57. Toronto, Ontario
  58. Montreal, Quebec
  59. Montréal, Quebec
  60. Brno,
  61. Prague 5,
  62. Praha 2,
  63. Lyon Cedex 03,
  64. Hamburg,
  65. Hannover,
  66. Muenchen,
  67. Beer Sheba,
  68. Haifa,
  69. Tel Hashomer,
  70. Tel-Aviv,
  71. Milan,
  72. Roma,
  73. Moelv,
  74. Oslo,
  75. Myslowice,
  76. Warszawa,
  77. Skovde,
  78. Stockholm,
  79. Balcali, Adana
  80. Samanpazari, Ankara
  81. Balcova, Izmir
  82. Nr Lichfield, Staffordshire
  83. Devon,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Assessment Of Safety Of UK-390,957
Official Title  ICMJE A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation
Brief Summary To determine whether UK-390,957 is a safe treatment for premature ejaculation.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Ejaculation
Intervention  ICMJE Drug: UK-390,957
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 14, 2005)		1058
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE March 2006
Actual Primary Completion Date March 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV

Exclusion Criteria:

  • No drug related serious adverse events
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Canada,   Czech Republic,   France,   Germany,   Israel,   Italy,   Norway,   Poland,   Sweden,   Turkey,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00219609
Other Study ID Numbers  ICMJE A3871028
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP